THL Credit Inc. 6.75% Notes du

TScan Therapeutics Inc. a clinical-stage biopharmaceutical company develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200 TSC-201 TSC-202 TSC-203 and TSC-205 for the treatment of solid tumors. In addition it engages in the developing vaccines for infectious diseases such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research Inc. to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics Inc. was incorporated in 2018 and is headquartered in Waltham Massachusetts.